Opposing Effects of Cyclooxygenase-2 (COX-2) on Estrogen Receptor (ER) Response to 5-reductase Inhibition in Prostate Epithelial Cells
Transcriptomics Dataset
FAIR Metrics
0 evaluations
General Information
| Accession | GSE80979 |
| Title | Opposing Effects of Cyclooxygenase-2 (COX-2) on Estrogen Receptor (ER) Response to 5-reductase Inhibition in Prostate Epithelial Cells |
| Description | Current pharmacotherapies for symptomatic benign prostatic hyperplasia (BPH), an androgen receptor (AR) driven, inflammatory disorder affecting elderly men, include 5-reductase (5AR) inhibitors (i.e. dutasteride and finasteride) to block the conversion of testosterone to the more potent AR ligand dihydrotestosterone (DHT). Since DHT is the precursor for estrogen receptor (ER) ligands, 5AR inhibitors could potentially limit ER activation, which maintains prostate tissue homeostasis. We have uncovered signaling pathways in BPH-derived prostate epithelial cells (BPH-1) that are impacted by 5AR inhibition. The induction of apoptosis and repression of the cell-adhesion protein E-cadherin by the 5AR inhibitor, dutasteride, requires both ER and TGF. Dutasteride also induces cyclooxygenase type 2 (COX-2), which functions in a negative-feedback loop in TGF and ER signaling pathways as evidenced by the potentiation of apoptosis induced by dutasteride or finasteride upon pharmacological inhibition or shRNA-mediated ablation of COX-2. Concurrently, COX-2 positively impacts ER action through its effect on the expression of a number of steroidogenic enzymes in the ER-ligand metabolic pathway. Therefore, effective combination pharmacotherapies, which have included non-steroidal anti-inflammatory drugs, must take into account biochemical pathways affected by 5AR inhibition and opposing effects of COX-2 on the tissue protective action of ER. |
| Landing Page | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80979 |
| Repository | Gene Expression Omnibus |
Tools
used to analyze the dataset
Canned Analyses
generated with the dataset
FAIR Evaluation
Sorry, you must be signed in to evaluate this object.
